D-0390-2025 Class II Ongoing
FDA drug recall D-0390-2025 was initiated by Eugia US LLC on Apr 21, 2025 and is designated Class II. Reason for recall: Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances. The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- May 7, 2025
- Initiation Date
- Apr 21, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-430-01
Reason for recall
Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.
Distribution pattern
USA nationwide.
Code information
Lot# : 3TF24001, Exp 3/31/2026
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0390-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026